a-s-wierzbicki documents

Lipid lowering, statins and cancer
Documents Lipid lowering, statins and cancer
Rimonabant: endocannabinoid inhibition for the metabolic syndrome
Documents Rimonabant: endocannabinoid inhibition for the metabolic syndrome
Quality as well as quantity? Beyond low-density lipoprotein-cholesterol – the role of particle size
Documents Quality as well as quantity? Beyond low-density lipoprotein-cholesterol – the role of particle size
Lipoproteins: from A to B and maybe C-III
Documents Lipoproteins: from A to B and maybe C-III
Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort
Documents Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort
A fishy business: omega-3 fatty acids and cardiovascular disease
Documents A fishy business: omega-3 fatty acids and cardiovascular disease
Shielding the population from the metabolic syndrome? There is one born every minute
Documents Shielding the population from the metabolic syndrome? There is one born every minute
Surrogate markers, atherosclerosis and cardiovascular disease prevention
Documents Surrogate markers, atherosclerosis and cardiovascular disease prevention
Muddy waters: more stormy SEAS for ezetimibe
Documents Muddy waters: more stormy SEAS for ezetimibe
SEARCHing for JUPITER: starry-eyed optimism is not warranted
Documents SEARCHing for JUPITER: starry-eyed optimism is not warranted
Vascular risk screening: possible or too much, too soon?
Documents Vascular risk screening: possible or too much, too soon?
Putting protection first: vascular risk assessment in atypical populations
Documents Putting protection first: vascular risk assessment in atypical populations
Practice makes perfect: reflections on a primary care treatment-to-target study
Documents Practice makes perfect: reflections on a primary care treatment-to-target study
The Poly-pill: does it work and is chronic therapy acceptable?
Documents The Poly-pill: does it work and is chronic therapy acceptable?
Cardiovascular screening: which populations, what measures of risk?
Documents Cardiovascular screening: which populations, what measures of risk?
Niacin: the only vitamin that reduces cardiovascular events
Documents Niacin: the only vitamin that reduces cardiovascular events
Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study
Documents Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study
A renaissance for cardio-metabolic surgery: better outcomes and lower costs?
Documents A renaissance for cardio-metabolic surgery: better outcomes and lower costs?
The ezetimibe Jonah: the trials and tribulations of an unlucky drug
Documents The ezetimibe Jonah: the trials and tribulations of an unlucky drug
New lipid-lowering drugs: an update
Documents New lipid-lowering drugs: an update
Intervening on HDL-C: Is it possible? Does it work?
Documents Intervening on HDL-C: Is it possible? Does it work?